Many biotech companies will face "make-or-break moments" related to trial results and product approvals in 2008, industry expert Edward M. Rudnic said. United Therapeutics Corp. and GenVec are expecting clinical trial results of their drug candidates for pulmonary hypertension and pancreatic cancer, respectively, and MiddleBrook Pharmaceuticals and Vanda Pharmaceuticals are expecting FDA decisions on drugs for amoxicillin and schizophrenia.

Related Summaries